This inter-agency guidance document aims to supplement the COVAX demand creation package for COVID-19 vaccines with key considerations for humanitarian contexts and marginalized populations with specific access and communication needs.
21 Sept.2021
PLoS Negl TropDis14(10): e0008837. https://doi.org/ 10.1371/journal.pntd.0008837.
We conducted alandscape analysis on parasitic and vector-borne disease elimination approaches with the aim toidentify evidence-based strategies, core components and key concepts for achieving and sustaining schistosom...iasis control and for progressing elimination efforts towards interruption oftransmission insubSaharan Africa.
more
Strengthening health-system emergency preparedness.
Examination of the business behaviour of Boehringer Ingelheim, Bayer and Baxter in Uganda
This policy brief is targeted at national governments, donors and regional and international actors to support Ebola-affected countries to transition from emergency response to recovery.
This paper is an initial compilation of the promising practices on risk communication and community engagement that have developed in Europe during the COVID pandemic, in complementarity to the UNHCR’s Practical Recommendations and Good Practice to Address Protection Concerns in the Context of the... COVID-19 Pandemic.It seeks to document and share such practices, but also to inspire new initiatives, foster exchange, and further develop a community of practice within the region.
more
Impact Evalution Report 61
Operational Guidelines and Field Manual on Human Rights Protection in Situations of Natural Disaster
These Guidelines comprise a General Guidelines document that provides the basic parameters of DG ECHO humanitarian health assistance, complemented by specific Technical Guidance in annex.
In Kenya, the bacterial infections that contribute most to human disease are often those in which re-‐sistance is most evident. Examples are multidrug-‐resistant enteric bacterial pathogens such as typhoid, ... diarrhoeagenic Escherichia coli and invasive non-‐typhi salmonella, penicillin-‐resistant Streptococcus pneu-‐moniae, vancomycin-‐resistant enterococci, methicillin-‐resistant Staphylococcus aureus and multidrug-‐re-‐sistant Mycobacterium tuberculosis. Resistance to medicines commonly used to treat malaria is of particu-‐lar concern, as is the emerging resistance to anti-‐HIV drugs. Often, more expensive medicines are required to treat these infections, and this becomes a major challenge in resource-‐poor settings.
more